Skip to content
‹ Back to IndustriesSciences

Terminator-Inspired Shape-Shifting Robot Becomes Reality. What Use Cases Does It Have in Manufacturing?

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end. The new robot was…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · Liquid Metal RobotMagnetoactive Phase Transitional MatterManufacturingMptm
Share

Key takeaways

01

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist.

02

This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers.

03

However, that’s where the similarities end.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end.

The new robot was developed by a team from The Chinese University of Hong Kong under the direction of Dr. Chengfeng Pan. It is made up of a newly developed phase-shifting material researchers call “magnetoactive liquid-solid phase transitional matter,” or MPTM. Magnetic particles embedded in the material of the robot allow users to control it. This means it can be heated and cooled on demand using an alternating magnetic field to melt it into a liquid and then solidify it again.

This research is just one of the many advancements shaping the future of robotics and its use cases. Scientists are hoping that this discovery will one day be of use in a variety of fields, including medicine and assembly lines. MPTM could make it easier to solder and screw parts in hard-to-reach places, for example, but that’s hopefully just scratching the surface of its utility.

How can the manufacturing industry benefit from a shape-shifting robot? And are there any manufacturing applications where a flexible structure can make a huge difference? We reached out to Rhonda DiBachi, CEO of HeyScottie, for her expert opinion and analysis on this T-1000 tech. Rhonda has been implementing manufacturing techniques for companies since the 1980s and founded numerous startups for tech and manufacturing. 

Rhonda’s Thoughts:

“I don’t know of any manufacturing applications for this new material called MPTM or Magnetoactive Phase Transitional Matter. It’s early days. I do know of some applications of a similar kind of material called a shape memory alloy. That’s metals that change their shape depending upon changes in temperature and pressure.

I know that those are used in pneumatic and flow control systems to change valves. That’s interesting. An interesting application for this new kind of material, MPTM, I would think would be 3D printing, metal 3D printing. You could create struts using this material and when you’re building up the part you could use the struts, they would be structural.

But then when you’re done building up the part, you don’t need the struts anymore. And, if you could flip a switch and make them change their shape, they might be able to just slither out, making removal quite a bit easier than it is right now. Could be interesting.”

Article written by Sonia Gossai.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent’s 5987A GC/MSD adds vendor-claimed up to 25% faster scanning and a wider detector range alongside GC Assist diagnostics tracking 60-plus parameters. Its design focuses on taking injections out of workflows to limit reruns. With helium spot prices reportedly doubling after the March 2026 disruption, avoided reruns can save gas, but EPA criteria checks and ISO/IEC 17025 verification still come first.

  • 01Injection-cutting features can matter most: MassHunter’s simultaneous dSIM/Scan to combine SIM quantitation and library-searchable full scan in one run, and Agilent’s claim of an order-of-magnitude wider dynamic range that could reduce dilution reinjections if it holds up in routine use.
  • 02Onboard diagnostics pay back unevenly. Labs that find faults by failing QC batches stand to gain the most, while labs on comprehensive service contracts may mainly change which contract tier they buy.
  • 03The up-to-40% energy cut applies with the IDP-4 pump, so bid scoring should confirm the quoted configuration before crediting the savings.

Nov 10, 2026

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM platform

UCB commits to Veeva Vault CRM platform

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show whether a worldwide migration is moving.

Nov 7, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512